Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

AbbVie (ABBV) Financials

AbbVie logo
$210.28 +0.78 (+0.37%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$210.12 -0.17 (-0.08%)
As of 08/22/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for AbbVie

Annual Income Statements for AbbVie

This table shows AbbVie's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 1,774 5,144 5,953 5,309 5,687 7,882 4,616 11,542 11,836 4,863 4,278
Consolidated Net Income / (Loss)		 1,774 5,144 5,953 5,309 5,687 7,882 4,622 11,549 11,845 4,873 4,286
Net Income / (Loss) Continuing Operations		 1,774 5,144 5,953 5,309 5,687 7,882 4,622 11,549 11,845 4,873 4,286
Total Pre-Tax Income 		2,369 6,645 7,884 7,727 5,197 8,426 3,398 12,989 13,477 6,250 3,716
Total Operating Income		 3,411 7,537 9,340 9,545 6,383 12,983 11,363 17,924 18,117 12,757 9,137
Total Gross Profit		 15,534 18,359 19,806 21,174 25,035 25,827 29,041 38,751 39,943 33,125 39,430
Total Revenue		 19,960 22,859 25,638 28,216 32,753 33,266 45,804 56,197 58,054 54,318 56,334
Operating Revenue		 19,960 22,859 25,638 28,216 32,753 33,266 45,804 56,197 58,054 54,318 56,334
Total Cost of Revenue		 4,426 4,500 5,832 7,042 7,718 7,439 16,763 17,446 18,111 21,193 16,904
Operating Cost of Revenue		 4,426 4,500 5,832 7,042 7,718 7,439 16,763 17,446 18,111 21,193 16,904
Total Operating Expenses		 12,123 10,822 10,466 11,629 18,652 12,844 17,678 20,827 21,826 20,368 30,293
Selling, General & Admin Expense		 8,474 6,387 5,881 6,295 7,399 6,942 11,299 13,473 15,260 12,872 17,509
Research & Development Expense		 3,649 4,435 4,585 5,334 10,753 6,792 6,379 6,922 6,510 7,675 12,791
Other Operating Expenses / (Income)		 - - - 0.00 500 -890 0.00 432 56 -179 -7.00
Total Other Income / (Expense), net		 -1,042 -892 -1,456 -1,818 -1,186 -4,557 -7,965 -4,935 -4,640 -6,507 -5,421
Interest & Investment Income		 -391 -686 -965 -1,004 -1,144 -1,509 -2,280 -2,384 -2,044 -1,684 -2,160
Other Income / (Expense), net		 -651 -206 -491 -814 -42 -3,048 -5,685 -2,551 -2,596 -4,823 -3,261
Income Tax Expense		 595 1,501 1,931 2,418 -490 544 -1,224 1,440 1,632 1,377 -570
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - 0.00 0.00 6.00 7.00 9.00 10 8.00
Basic Earnings per Share		 $1.11 $3.15 $3.65 $3.31 $3.67 $5.30 $2.73 $6.48 $6.65 $2.73 $2.40
Weighted Average Basic Shares Outstanding		 1.60B 1.63B 1.62B 1.60B 1.54B 1.48B 1.67B 1.77B 1.77B 1.77B 1.77B
Diluted Earnings per Share		 $1.10 $3.13 $3.63 $3.30 $3.66 $5.28 $2.72 $6.45 $6.63 $2.72 $2.39
Weighted Average Diluted Shares Outstanding		 1.61B 1.64B 1.63B 1.60B 1.55B 1.48B 1.67B 1.78B 1.78B 1.77B 1.77B
Weighted Average Basic & Diluted Shares Outstanding		 1.60B 1.63B 1.63B 1.60B 1.55B 1.48B 1.77B 1.77B 1.77B 1.77B 1.77B

Quarterly Income Statements for AbbVie

This table shows AbbVie's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 2,473 239 2,024 1,778 822 1,369 1,370 1,561 -22 1,286 938
Consolidated Net Income / (Loss)		 2,472 241 2,027 1,781 824 1,372 1,373 1,564 -23 1,289 941
Net Income / (Loss) Continuing Operations		 2,472 241 2,027 1,781 824 1,372 1,373 1,564 -23 1,289 941
Total Pre-Tax Income 		2,965 475 2,610 1,953 1,212 1,755 2,146 2,084 -2,269 1,661 1,554
Total Operating Income		 5,502 2,768 4,513 2,281 3,195 2,798 3,998 3,831 -1,490 3,733 4,894
Total Gross Profit		 10,708 8,089 9,625 7,376 8,035 8,052 10,260 10,248 11,807 9,093 11,077
Total Revenue		 15,121 12,225 13,865 13,927 14,301 12,310 14,462 14,460 15,102 13,343 15,423
Operating Revenue		 15,121 12,225 13,865 13,927 14,301 12,310 14,462 14,460 15,102 13,343 15,423
Total Cost of Revenue		 4,413 4,136 4,240 6,551 6,266 4,258 4,202 4,212 3,295 4,250 4,346
Operating Cost of Revenue		 4,413 4,136 4,240 6,551 6,266 4,258 4,202 4,212 3,295 4,250 4,346
Total Operating Expenses		 5,206 5,321 5,112 5,095 4,840 5,254 6,262 6,417 13,297 5,360 6,183
Selling, General & Admin Expense		 3,417 3,039 3,548 3,372 2,913 3,315 4,314 4,287 6,530 3,293 4,076
Research & Development Expense		 1,790 2,292 1,733 1,723 1,927 1,939 1,948 2,130 6,774 2,067 2,131
Other Operating Expenses / (Income)		 -1.00 -10 -169 0.00 - - 0.00 0.00 -7.00 - -24
Total Other Income / (Expense), net		 -2,537 -2,293 -1,903 -328 -1,983 -1,043 -1,852 -1,747 -779 -2,072 -3,340
Interest & Investment Income		 -476 -454 -454 -398 -378 -453 -506 -591 -610 -627 -678
Other Income / (Expense), net		 -2,061 -1,839 -1,449 70 -1,605 -590 -1,346 -1,156 -169 -1,445 -2,662
Income Tax Expense		 493 234 583 172 388 383 773 520 -2,246 372 613
Net Income / (Loss) Attributable to Noncontrolling Interest		 -1.00 2.00 3.00 3.00 2.00 3.00 3.00 3.00 -1.00 3.00 3.00
Basic Earnings per Share		 $1.39 $0.13 $1.14 $1.00 $0.46 $0.77 $0.77 $0.88 ($0.02) $0.72 $0.52
Weighted Average Basic Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Diluted Earnings per Share		 $1.40 $0.13 $1.14 $1.00 $0.45 $0.77 $0.77 $0.88 ($0.03) $0.72 $0.52
Weighted Average Diluted Shares Outstanding		 1.78B 1.78B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Weighted Average Basic & Diluted Shares Outstanding		 1.77B 1.76B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Cash Dividends to Common per Share		 - - - - - $1.55 $1.55 - - $1.64 $1.64

Annual Cash Flow Statements for AbbVie

This table details how cash moves in and out of AbbVie's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -2,456 51 -3,299 4,203 -2,014 32,635 -31,475 1,297 -545 3,613 -7,290
Net Cash From Operating Activities		 1,775 7,535 7,041 9,960 13,427 13,324 17,588 22,777 24,943 22,839 18,806
Net Cash From Continuing Operating Activities		 1,775 7,535 7,041 9,960 13,427 13,324 17,588 22,777 24,943 22,839 18,806
Net Income / (Loss) Continuing Operations		 0.00 5,144 5,953 5,309 5,687 7,882 4,622 11,549 11,845 4,873 4,286
Consolidated Net Income / (Loss)		 - 5,144 5,953 5,309 5,687 7,882 4,622 11,549 11,845 4,873 4,286
Depreciation Expense		 383 417 425 425 471 464 666 803 778 752 764
Amortization Expense		 403 419 764 1,076 1,294 1,553 5,805 7,718 7,689 7,946 7,622
Non-Cash Adjustments To Reconcile Net Income		 1,777 1,051 1,360 2,515 7,052 1,663 2,961 2,157 3,895 4,216 6,594
Changes in Operating Assets and Liabilities, net		 -788 504 -1,461 635 -1,077 1,762 3,534 550 736 5,052 -460
Net Cash From Investing Activities		 -926 -12,936 -6,074 -274 -1,006 596 -37,557 -2,344 -623 -2,009 -20,820
Net Cash From Continuing Investing Activities		 -926 -12,936 -6,074 -274 -1,006 596 -37,557 -2,344 -623 -2,009 -20,820
Purchase of Property, Plant & Equipment		 -612 -532 -479 -529 -638 -552 -798 -787 -695 -777 -974
Acquisitions		 0.00 -11,488 -2,495 - 0.00 0.00 -38,260 -525 -255 0.00 -17,493
Purchase of Investments		 -1,791 -1,815 -5,577 -2,538 -2,528 -1,718 -1,411 -1,496 -1,977 -1,300 -3,097
Sale and/or Maturity of Investments		 1,477 899 2,359 2,793 2,160 2,699 1,525 98 1,530 55 555
Other Investing Activities, net		 0.00 0.00 118 0.00 0.00 167 1,387 366 774 13 189
Net Cash From Financing Activities		 -3,305 5,771 -3,928 -5,512 -14,396 18,708 -11,501 -19,039 -24,803 -17,222 -5,211
Net Cash From Continuing Financing Activities		 -3,305 5,771 -3,928 -5,512 -14,396 18,708 -11,501 -19,039 -24,803 -17,222 -5,211
Repayment of Debt		 -17 -4,018 -6,010 -25 -6,035 -4,501 -5,675 -9,390 -14,403 -4,101 -14,564
Repurchase of Common Equity		 -806 -7,768 -6,102 -1,410 -12,054 -1,053 -998 -934 -1,487 -2,010 -1,807
Payment of Dividends		 -2,661 -3,294 -3,717 -4,107 -5,580 -6,366 -7,716 -9,261 -10,043 -10,539 -11,025
Issuance of Debt		 -53 20,696 11,633 44 9,278 30,783 3,000 1,000 2,000 0.00 21,971
Other Financing Activities, net		 232 155 268 -14 -5.00 -155 -112 -454 -870 -572 214
Effect of Exchange Rate Changes		 - - -338 29 -39 7.00 -5.00 -97 -62 5.00 -65
Cash Interest Paid		 - 536 986 1,099 1,215 1,794 2,619 2,712 2,546 2,469 2,811
Cash Income Taxes Paid		 - 1,108 3,563 1,696 0.00 1,447 1,674 3,648 2,988 4,702 4,064

Quarterly Cash Flow Statements for AbbVie

This table details how cash moves in and out of AbbVie's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Change in Cash & Equivalents		 -2,631 -2,490 2,048 4,528 -473 5,253 -4,937 -5,873 -1,733 -349 1,292
Net Cash From Operating Activities		 7,428 4,193 6,319 7,574 4,753 4,040 2,271 5,447 7,048 1,635 5,153
Net Cash From Continuing Operating Activities		 7,428 4,193 6,319 7,574 4,753 4,040 2,271 5,447 7,048 1,635 5,153
Net Income / (Loss) Continuing Operations		 2,472 241 2,027 1,781 824 1,372 1,373 1,564 -23 1,289 941
Consolidated Net Income / (Loss)		 2,472 241 2,027 1,781 824 1,372 1,373 1,564 -23 1,289 941
Depreciation Expense		 196 179 190 196 187 183 184 191 206 181 186
Amortization Expense		 1,961 1,948 2,070 2,039 1,889 1,891 1,947 1,888 1,896 1,858 1,864
Non-Cash Adjustments To Reconcile Net Income		 355 1,031 294 1,786 1,105 76 689 -25 5,854 -603 201
Changes in Operating Assets and Liabilities, net		 2,444 794 1,738 1,772 748 518 -1,922 1,829 -885 -1,090 1,961
Net Cash From Investing Activities		 -448 -499 -341 -369 -800 -9,588 -1,102 -8,256 -1,874 -735 -1,181
Net Cash From Continuing Investing Activities		 -448 -499 -341 -369 -800 -9,588 -1,102 -8,256 -1,874 -735 -1,181
Purchase of Property, Plant & Equipment		 -213 -175 -178 -219 -205 -193 -241 -249 -291 -235 -269
Purchase of Investments		 -55 -372 -176 -165 -587 -196 -859 -223 -1,819 -344 -952
Sale and/or Maturity of Investments		 70 22 14 5.00 14 6.00 3.00 507 39 32 7.00
Other Investing Activities, net		 5.00 26 -1.00 10 -22 -6.00 -5.00 3.00 197 16 33
Net Cash From Financing Activities		 -9,634 -6,192 -3,920 -2,661 -4,449 10,819 -6,097 -3,072 -6,861 -1,258 -2,710
Net Cash From Continuing Financing Activities		 -9,634 -6,192 -3,920 -2,661 -4,449 10,819 -6,097 -3,072 -6,861 -1,258 -2,710
Repayment of Debt		 -6,862 -1,330 -1,003 28 -1,796 -5,183 -3,348 -371 -5,662 -3,015 -3,756
Repurchase of Common Equity		 -4.00 -1,955 -10 -4.00 -41 -1,324 -9.00 -17 -457 -961 -12
Payment of Dividends		 -2,506 -2,661 -2,625 -2,627 -2,626 -2,772 -2,750 -2,751 -2,752 -2,925 -2,910
Issuance of Debt		 - 0.00 - - - 19,971 - - 2,000 5,587 3,963
Other Financing Activities, net		 -262 -246 -282 -58 14 127 10 67 10 56 5.00
Effect of Exchange Rate Changes		 23 8.00 -10 -16 23 -18 -9.00 8.00 -46 9.00 30

Annual Balance Sheets for AbbVie

This table presents AbbVie's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 27,513 53,050 66,099 70,786 59,352 89,115 150,565 146,529 138,805 134,711 135,161
Total Current Assets		 16,081 16,314 16,187 21,223 16,945 49,519 24,173 27,928 28,463 33,002 25,582
Cash & Equivalents		 8,348 8,399 5,100 9,303 7,289 39,924 8,449 9,746 9,201 12,814 5,524
Short-Term Investments		 26 8.00 1,323 486 772 0.00 30 84 28 2.00 31
Accounts Receivable		 3,735 4,730 4,758 5,088 5,384 5,428 8,822 9,977 11,254 11,155 10,919
Inventories, net		 1,124 1,719 1,444 1,605 1,605 1,813 3,310 3,128 3,579 4,099 4,181
Prepaid Expenses		 1,952 1,458 3,562 4,741 1,895 2,354 3,562 4,993 4,401 4,932 4,927
Plant, Property, & Equipment, net		 2,485 2,565 2,604 2,803 2,883 2,962 5,248 5,110 4,935 4,989 5,134
Total Noncurrent Assets		 8,947 34,171 47,308 46,760 39,524 36,634 121,144 113,491 105,407 96,720 104,445
Long-Term Investments		 92 145 1,783 2,090 1,420 93 293 277 241 304 279
Goodwill		 5,862 13,168 15,416 15,785 15,663 15,604 33,124 32,379 32,156 32,293 34,956
Intangible Assets		 1,513 19,709 28,897 27,559 21,233 18,649 82,876 75,951 67,439 55,610 60,068
Other Noncurrent Operating Assets		 1,480 1,149 1,212 1,326 1,208 2,288 4,851 4,884 5,571 8,513 9,142
Total Liabilities & Shareholders' Equity		 27,513 53,050 66,099 70,786 59,352 89,115 150,565 146,529 138,805 134,711 135,161
Total Liabilities		 25,771 49,105 61,463 65,689 67,798 97,287 137,468 131,093 121,518 124,314 131,797
Total Current Liabilities		 11,393 10,894 9,781 16,641 17,239 15,585 28,661 35,194 29,538 37,841 38,749
Short-Term Debt		 4,439 2,431 402 6,415 5,308 3,753 8,502 12,495 4,136 7,191 6,804
Accounts Payable		 6,954 8,463 9,379 10,226 11,931 11,832 20,159 22,699 25,402 30,650 31,945
Total Noncurrent Liabilities		 14,378 38,211 51,682 49,048 50,559 81,702 108,807 95,899 91,980 86,473 93,048
Long-Term Debt		 14,219 32,935 44,792 46,558 49,492 62,975 77,554 64,189 59,135 52,194 60,340
Noncurrent Deferred & Payable Income Tax Liabilities		 159 5,276 6,890 2,490 1,067 1,130 3,646 3,009 2,190 1,952 2,579
Other Noncurrent Operating Liabilities		 - - - - - 17,597 27,607 28,701 30,655 32,327 30,129
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,742 3,945 4,636 5,097 -8,446 -8,172 13,097 15,436 17,287 10,397 3,364
Total Preferred & Common Equity		 1,742 3,945 4,636 5,097 -8,446 -8,172 13,076 15,408 17,254 10,360 3,325
Total Common Equity		 1,742 3,945 4,636 5,097 -8,446 -8,172 13,076 15,408 17,254 10,360 3,325
Common Stock		 4,210 13,097 13,696 14,288 14,774 15,211 17,402 18,323 19,263 20,198 21,351
Retained Earnings		 535 2,248 4,378 5,459 3,368 4,717 1,055 3,127 4,784 -1,000 -7,900
Treasury Stock		 -972 -8,839 -10,852 -11,923 -24,108 -24,504 -2,264 -3,143 -4,594 -6,533 -8,201
Accumulated Other Comprehensive Income / (Loss)		 -2,031 -2,561 -2,586 -2,727 -2,480 -3,596 -3,117 -2,899 -2,199 -2,305 -1,925
Noncontrolling Interest		 - - - - - 0.00 21 28 33 37 39

Quarterly Balance Sheets for AbbVie

This table presents AbbVie's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Total Assets		 138,805 134,544 135,367 136,221 134,711 148,874 141,937 143,422 135,161 136,165 137,182
Total Current Assets		 28,463 26,488 28,852 33,224 33,002 38,871 33,816 27,785 25,582 27,675 29,261
Cash & Equivalents		 9,201 6,711 8,759 13,287 12,814 18,067 13,130 7,257 5,524 5,175 6,467
Short-Term Investments		 28 11 7.00 3.00 2.00 2.00 27 28 31 1.00 0.00
Accounts Receivable		 11,254 11,473 11,491 11,412 11,155 11,949 11,724 11,472 10,919 12,477 12,637
Inventories, net		 3,579 3,833 4,055 3,981 4,099 4,245 4,218 4,450 4,181 4,526 4,960
Prepaid Expenses		 4,401 4,460 4,540 4,541 4,932 4,608 4,717 4,578 4,927 5,496 5,197
Plant, Property, & Equipment, net		 4,935 4,931 4,943 4,934 4,989 4,980 5,023 5,141 5,134 5,237 5,283
Total Noncurrent Assets		 105,407 103,125 101,572 98,063 96,720 105,023 103,098 110,496 104,445 103,253 102,638
Long-Term Investments		 241 257 288 275 304 305 272 267 279 287 310
Goodwill		 32,156 32,220 32,224 32,091 32,293 33,426 33,386 35,295 34,956 35,285 35,638
Intangible Assets		 67,439 64,848 62,862 58,603 55,610 62,225 60,243 66,646 60,068 58,489 57,031
Other Noncurrent Operating Assets		 5,571 5,800 6,198 7,094 8,513 9,067 9,197 8,288 9,142 9,192 9,659
Total Liabilities & Shareholders' Equity		 138,805 134,544 135,367 136,221 134,711 148,874 141,937 143,422 135,161 136,165 137,182
Total Liabilities		 121,518 121,241 122,469 124,092 124,314 140,827 135,116 137,351 131,797 134,703 137,320
Total Current Liabilities		 29,538 27,590 32,239 34,773 37,841 41,522 41,915 43,062 38,749 36,403 39,767
Short-Term Debt		 4,136 2,801 5,203 5,115 7,191 10,196 12,586 12,570 6,804 5,362 7,522
Accounts Payable		 25,402 24,789 27,036 29,658 30,650 31,326 29,329 30,492 31,945 31,041 32,245
Total Noncurrent Liabilities		 91,980 93,651 90,230 89,319 86,473 99,305 93,201 94,289 93,048 98,300 97,553
Long-Term Debt		 59,135 59,292 55,812 55,631 52,194 63,805 58,048 58,509 60,340 64,527 62,959
Noncurrent Deferred & Payable Income Tax Liabilities		 2,190 2,110 2,124 2,044 1,952 2,722 2,726 2,749 2,579 2,582 2,554
Other Noncurrent Operating Liabilities		 30,655 32,249 32,294 31,644 32,327 32,778 32,427 33,031 30,129 31,191 32,040
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 17,287 13,303 12,898 12,129 10,397 8,047 6,821 6,071 3,364 1,462 -138
Total Preferred & Common Equity		 17,254 13,274 12,866 12,094 10,360 8,007 6,778 6,032 3,325 1,420 -183
Total Common Equity		 17,254 13,274 12,866 12,094 10,360 8,007 6,778 6,032 3,325 1,420 -183
Common Stock		 19,263 19,637 19,857 20,039 20,198 20,674 20,897 21,178 21,351 21,826 22,005
Retained Earnings		 4,784 2,393 1,789 933 -1,000 -2,384 -3,768 -4,964 -7,900 -9,527 -11,503
Treasury Stock		 -4,594 -6,524 -6,528 -6,525 -6,533 -7,829 -7,838 -7,848 -8,201 -9,137 -9,147
Accumulated Other Comprehensive Income / (Loss)		 -2,199 -2,232 -2,252 -2,353 -2,305 -2,454 -2,513 -2,334 -1,925 -1,742 -1,538
Noncontrolling Interest		 33 29 32 35 37 40 43 39 39 42 45

Annual Metrics And Ratios for AbbVie

This table displays calculated financial ratios and metrics derived from AbbVie's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 6.23% 14.52% 12.16% 10.06% 16.08% 1.57% 37.69% 22.69% 3.30% -6.44% 3.71%
EBITDA Growth		 -45.50% 130.32% 22.91% 1.93% -20.78% 47.45% 1.65% 96.67% 0.39% -30.67% -14.25%
EBIT Growth		 -50.80% 165.62% 20.71% -1.33% -27.37% 56.68% -42.85% 170.75% 0.96% -48.88% -25.94%
NOPAT Growth		 -41.75% 128.42% 20.87% -7.01% 6.51% 73.87% 27.27% 3.11% -0.09% -37.54% 5.95%
Net Income Growth		 -57.03% 189.97% 15.73% -10.82% 7.12% 38.60% -41.36% 149.87% 2.56% -58.86% -12.05%
EPS Growth		 -57.03% 184.55% 15.97% -9.09% 10.91% 44.26% -48.48% 137.13% 2.79% -58.97% -12.13%
Operating Cash Flow Growth		 -71.68% 324.51% -6.56% 41.46% 34.81% -0.77% 32.00% 29.50% 9.51% -8.44% -17.66%
Free Cash Flow Firm Growth		 -30.45% -486.93% 70.65% 152.22% 718.79% 86.95% -285.00% 143.10% 10.46% -9.22% -89.63%
Invested Capital Growth		 -6.30% 157.74% 35.32% 10.97% -20.17% -49.72% 387.52% -9.26% -13.32% -20.29% 14.14%
Revenue Q/Q Growth		 1.74% 4.33% 1.57% 3.46% 1.76% 1.21% 12.68% 1.86% 0.41% -1.49% 1.44%
EBITDA Q/Q Growth		 -40.58% 61.15% 2.37% -7.27% -29.71% 89.65% -19.07% 30.93% -4.85% -10.41% -18.43%
EBIT Q/Q Growth		 -46.67% 70.49% 1.90% -8.81% -35.56% 128.29% -43.76% 59.44% -8.28% -18.92% -35.61%
NOPAT Q/Q Growth		 -37.81% 52.33% -0.86% -16.48% -23.71% 68.77% 44.38% -8.22% -0.83% -18.97% 6.90%
Net Income Q/Q Growth		 -52.21% 82.61% -2.07% -20.14% -24.82% 142.15% -37.41% 53.13% -11.72% -25.27% -16.50%
EPS Q/Q Growth		 -52.17% 84.12% -2.16% -19.71% 0.00% 0.00% -42.49% 58.87% -11.48% -25.89% -16.72%
Operating Cash Flow Q/Q Growth		 -72.03% 27.73% -5.65% 11.70% 6.40% -0.87% 9.86% 0.98% 10.42% -10.48% 13.90%
Free Cash Flow Firm Q/Q Growth		 -25.47% 18.52% -8.45% -75.09% 102.47% 104.98% -17.32% -18.28% 10.42% -7.97% 687.62%
Invested Capital Q/Q Growth		 2.04% -2.25% -1.12% 10.09% -14.37% -47.61% -4.01% 0.29% -3.31% -4.46% -7.07%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 77.83% 80.31% 77.25% 75.04% 76.44% 77.64% 63.40% 68.96% 68.80% 60.98% 69.99%
EBITDA Margin		 17.77% 35.73% 39.15% 36.26% 24.75% 35.93% 26.52% 42.52% 41.32% 30.62% 25.32%
Operating Margin		 17.09% 32.97% 36.43% 33.83% 19.49% 39.03% 24.81% 31.89% 31.21% 23.49% 16.22%
EBIT Margin		 13.83% 32.07% 34.52% 30.94% 19.36% 29.87% 12.40% 27.36% 26.74% 14.61% 10.43%
Profit (Net Income) Margin		 8.89% 22.50% 23.22% 18.82% 17.36% 23.69% 10.09% 20.55% 20.40% 8.97% 7.61%
Tax Burden Percent		 74.88% 77.41% 75.51% 68.71% 109.43% 93.54% 136.02% 88.91% 87.89% 77.97% 115.34%
Interest Burden Percent		 85.83% 90.64% 89.09% 88.50% 81.96% 84.81% 59.85% 84.49% 86.83% 78.77% 63.24%
Effective Tax Rate		 25.12% 22.59% 24.49% 31.29% -9.43% 6.46% -36.02% 11.09% 12.11% 22.03% -15.34%
Return on Invested Capital (ROIC)		 20.71% 27.33% 19.49% 14.94% 16.82% 43.83% 28.38% 18.49% 20.80% 15.57% 17.37%
ROIC Less NNEP Spread (ROIC-NNEP)		 12.24% 23.60% 16.04% 11.74% 13.81% 32.00% 7.54% 12.39% 14.03% 5.43% 5.75%
Return on Net Nonoperating Assets (RNNOA)		 36.21% 153.57% 119.26% 94.16% -356.44% -138.70% 159.31% 62.46% 51.59% 19.63% 44.92%
Return on Equity (ROE)		 56.91% 180.90% 138.75% 109.09% -339.62% -94.86% 187.70% 80.95% 72.40% 35.20% 62.29%
Cash Return on Invested Capital (CROIC)		 27.22% -60.86% -10.53% 4.53% 39.25% 110.01% -103.54% 28.20% 35.07% 38.16% 4.16%
Operating Return on Assets (OROA)		 9.73% 18.20% 14.85% 12.76% 9.75% 13.38% 4.74% 10.35% 10.88% 5.80% 4.35%
Return on Assets (ROA)		 6.26% 12.77% 9.99% 7.76% 8.74% 10.62% 3.86% 7.77% 8.30% 3.56% 3.18%
Return on Common Equity (ROCE)		 56.91% 180.90% 138.75% 109.09% -339.62% -94.86% 186.90% 80.81% 72.26% 35.12% 61.95%
Return on Equity Simple (ROE_SIMPLE)		 101.84% 130.39% 128.41% 104.16% -67.33% -96.45% 35.35% 74.95% 68.65% 47.04% 128.90%
Net Operating Profit after Tax (NOPAT)		 2,554 5,835 7,052 6,558 6,985 12,145 15,456 15,937 15,923 9,946 10,539
NOPAT Margin		 12.80% 25.52% 27.51% 23.24% 21.33% 36.51% 33.74% 28.36% 27.43% 18.31% 18.71%
Net Nonoperating Expense Percent (NNEP)		 8.46% 3.73% 3.45% 3.20% 3.00% 11.84% 20.84% 6.10% 6.78% 10.14% 11.62%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 19.77% 14.25% 14.95%
Cost of Revenue to Revenue		 22.17% 19.69% 22.75% 24.96% 23.56% 22.36% 36.60% 31.04% 31.20% 39.02% 30.01%
SG&A Expenses to Revenue		 42.45% 27.94% 22.94% 22.31% 22.59% 20.87% 24.67% 23.97% 26.29% 23.70% 31.08%
R&D to Revenue		 18.28% 19.40% 17.88% 18.90% 32.83% 20.42% 13.93% 12.32% 11.21% 14.13% 22.71%
Operating Expenses to Revenue		 60.74% 47.34% 40.82% 41.21% 56.95% 38.61% 38.59% 37.06% 37.60% 37.50% 53.77%
Earnings before Interest and Taxes (EBIT)		 2,760 7,331 8,849 8,731 6,341 9,935 5,678 15,373 15,521 7,934 5,876
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 3,546 8,167 10,038 10,232 8,106 11,952 12,149 23,894 23,988 16,632 14,262
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 39.89 16.90 15.69 22.45 0.00 0.00 12.42 13.98 15.22 25.24 93.56
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 3.48 2.92 2.84 4.05 3.26 3.20 3.55 3.83 4.52 4.81 5.52
Price to Earnings (P/E)		 39.17 12.96 12.22 21.55 18.77 13.51 35.18 18.66 22.18 53.77 72.72
Dividend Yield		 3.81% 4.95% 5.09% 3.57% 5.06% 5.94% 5.13% 4.27% 3.80% 4.00% 3.52%
Earnings Yield		 2.55% 7.72% 8.18% 4.64% 5.33% 7.40% 2.84% 5.36% 4.51% 1.86% 1.38%
Enterprise Value to Invested Capital (EV/IC)		 6.68 3.04 2.64 3.37 4.12 7.19 2.65 3.44 4.45 5.43 5.76
Enterprise Value to Revenue (EV/Rev)		 3.99 4.09 4.28 5.51 4.64 4.00 5.23 5.02 5.45 5.67 6.61
Enterprise Value to EBITDA (EV/EBITDA)		 22.47 11.45 10.93 15.20 18.76 11.15 19.73 11.80 13.19 18.51 26.11
Enterprise Value to EBIT (EV/EBIT)		 28.87 12.75 12.40 17.81 23.98 13.41 42.22 18.34 20.38 38.79 63.38
Enterprise Value to NOPAT (EV/NOPAT)		 31.19 16.02 15.56 23.71 21.77 10.97 15.51 17.69 19.87 30.95 35.34
Enterprise Value to Operating Cash Flow (EV/OCF)		 44.89 12.41 15.59 15.61 11.33 10.00 13.63 12.38 12.68 13.48 19.80
Enterprise Value to Free Cash Flow (EV/FCFF)		 23.73 0.00 0.00 78.10 9.33 4.37 0.00 11.60 11.78 12.63 147.41
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 10.71 8.96 9.75 10.39 -6.49 -8.17 6.57 4.97 3.66 5.71 19.96
Long-Term Debt to Equity		 8.16 8.35 9.66 9.13 -5.86 -7.71 5.92 4.16 3.42 5.02 17.94
Financial Leverage		 2.96 6.51 7.44 8.02 -25.80 -4.33 21.12 5.04 3.68 3.61 7.82
Leverage Ratio		 9.10 14.17 13.89 14.06 -38.86 -8.93 48.67 10.41 8.72 9.88 19.61
Compound Leverage Factor		 7.81 12.84 12.37 12.45 -31.85 -7.58 29.12 8.80 7.57 7.78 12.40
Debt to Total Capital		 91.46% 89.96% 90.70% 91.22% 118.22% 113.96% 86.79% 83.24% 78.54% 85.10% 95.23%
Short-Term Debt to Total Capital		 21.76% 6.18% 0.81% 11.05% 11.45% 6.41% 8.57% 13.56% 5.13% 10.30% 9.65%
Long-Term Debt to Total Capital		 69.70% 83.78% 89.89% 80.18% 106.77% 107.55% 78.22% 69.68% 73.41% 74.80% 85.58%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.03% 0.04% 0.05% 0.06%
Common Equity to Total Capital		 8.54% 10.04% 9.30% 8.78% -18.22% -13.96% 13.19% 16.73% 21.42% 14.85% 4.72%
Debt to EBITDA		 5.26 4.33 4.50 5.18 6.76 5.58 7.08 3.21 2.64 3.57 4.71
Net Debt to EBITDA		 2.87 3.28 3.68 4.02 5.59 2.23 6.36 2.79 2.24 2.78 4.30
Long-Term Debt to EBITDA		 4.01 4.03 4.46 4.55 6.11 5.27 6.38 2.69 2.47 3.14 4.23
Debt to NOPAT		 7.30 6.06 6.41 8.08 7.85 5.49 5.57 4.81 3.97 5.97 6.37
Net Debt to NOPAT		 3.99 4.60 5.24 6.27 6.49 2.20 5.00 4.18 3.38 4.65 5.82
Long-Term Debt to NOPAT		 5.57 5.64 6.35 7.10 7.09 5.19 5.02 4.03 3.71 5.25 5.73
Altman Z-Score		 2.91 1.88 1.75 2.04 1.92 1.93 1.11 1.69 2.12 1.81 1.78
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.43% 0.17% 0.19% 0.25% 0.55%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.41 1.50 1.65 1.28 0.98 3.18 0.84 0.79 0.96 0.87 0.66
Quick Ratio		 1.06 1.21 1.14 0.89 0.78 2.91 0.60 0.56 0.69 0.63 0.43
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 3,357 -12,990 -3,813 1,991 16,303 30,479 -56,386 24,305 26,848 24,372 2,527
Operating Cash Flow to CapEx		 290.03% 1,416.35% 1,469.94% 1,882.80% 2,104.55% 2,413.77% 2,204.01% 2,894.16% 3,588.92% 2,939.38% 1,930.80%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.70 0.57 0.43 0.41 0.50 0.45 0.38 0.38 0.41 0.40 0.42
Accounts Receivable Turnover		 5.26 5.40 5.40 5.73 6.26 6.15 6.43 5.98 5.47 4.85 5.10
Inventory Turnover		 3.89 3.17 3.69 4.62 4.81 4.35 6.54 5.42 5.40 5.52 4.08
Fixed Asset Turnover		 8.35 9.05 9.92 10.44 11.52 11.38 11.16 10.85 11.56 10.95 11.13
Accounts Payable Turnover		 0.66 0.58 0.65 0.72 0.70 0.63 1.05 0.81 0.75 0.76 0.54
Days Sales Outstanding (DSO)		 69.39 67.58 67.54 63.68 58.35 59.32 56.78 61.05 66.74 75.29 71.51
Days Inventory Outstanding (DIO)		 93.77 115.30 98.98 79.02 75.90 83.85 55.77 67.35 67.58 66.12 89.39
Days Payable Outstanding (DPO)		 552.61 625.25 558.33 508.08 523.92 582.97 348.29 448.33 484.70 482.68 675.79
Cash Conversion Cycle (CCC)		 -389.46 -442.36 -391.81 -365.38 -389.67 -439.81 -235.74 -319.93 -350.37 -341.27 -514.89
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 11,934 30,759 41,624 46,191 36,873 18,539 90,381 82,013 71,088 56,662 64,674
Invested Capital Turnover		 1.62 1.07 0.71 0.64 0.79 1.20 0.84 0.65 0.76 0.85 0.93
Increase / (Decrease) in Invested Capital		 -803 18,825 10,865 4,567 -9,318 -18,334 71,842 -8,368 -10,925 -14,426 8,012
Enterprise Value (EV)		 79,676 93,473 109,742 155,500 152,086 133,216 239,699 281,950 316,377 307,792 372,436
Market Capitalization		 69,484 66,659 72,754 114,406 106,767 106,505 162,394 215,345 262,543 261,490 311,087
Book Value per Share		 $1.09 $2.41 $2.85 $3.19 ($5.61) ($5.53) $7.41 $8.72 $9.76 $5.87 $1.88
Tangible Book Value per Share		 ($3.54) ($17.70) ($24.42) ($23.96) ($30.14) ($28.69) ($58.30) ($52.56) ($46.56) ($43.92) ($51.89)
Total Capital		 20,400 39,311 49,830 58,070 46,354 58,556 99,153 92,120 80,558 69,782 70,508
Total Debt		 18,658 35,366 45,194 52,973 54,800 66,728 86,056 76,684 63,271 59,385 67,144
Total Long-Term Debt		 14,219 32,935 44,792 46,558 49,492 62,975 77,554 64,189 59,135 52,194 60,340
Net Debt		 10,192 26,814 36,988 41,094 45,319 26,711 77,284 66,577 53,801 46,265 61,310
Capital Expenditures (CapEx)		 612 532 479 529 638 552 798 787 695 777 974
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 753 -556 385 1,208 -3,047 -2,237 -4,465 -4,601 -6,168 -10,464 -11,918
Debt-free Net Working Capital (DFNWC)		 9,127 7,851 6,808 10,997 5,014 37,687 4,014 5,229 3,061 2,352 -6,363
Net Working Capital (NWC)		 4,688 5,420 6,406 4,582 -294 33,934 -4,488 -7,266 -1,075 -4,839 -13,167
Net Nonoperating Expense (NNE)		 780 691 1,099 1,249 1,298 4,263 10,834 4,388 4,078 5,073 6,253
Net Nonoperating Obligations (NNO)		 10,192 26,814 36,988 41,094 45,319 26,711 77,284 66,577 53,801 46,265 61,310
Total Depreciation and Amortization (D&A)		 786 836 1,189 1,501 1,765 2,017 6,471 8,521 8,467 8,698 8,386
Debt-free, Cash-free Net Working Capital to Revenue		 3.77% -2.43% 1.50% 4.28% -9.30% -6.72% -9.75% -8.19% -10.62% -19.26% -21.16%
Debt-free Net Working Capital to Revenue		 45.73% 34.35% 26.55% 38.97% 15.31% 113.29% 8.76% 9.30% 5.27% 4.33% -11.30%
Net Working Capital to Revenue		 23.49% 23.71% 24.99% 16.24% -0.90% 102.01% -9.80% -12.93% -1.85% -8.91% -23.37%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.11 $3.15 $3.65 $3.31 $3.67 $5.30 $2.73 $6.48 $6.65 $2.73 $2.40
Adjusted Weighted Average Basic Shares Outstanding		 1.60B 1.63B 1.62B 1.60B 1.54B 1.48B 1.67B 1.77B 1.77B 1.77B 1.77B
Adjusted Diluted Earnings per Share		 $1.10 $3.13 $3.63 $3.30 $3.66 $5.28 $2.72 $6.45 $6.63 $2.72 $2.39
Adjusted Weighted Average Diluted Shares Outstanding		 1.61B 1.64B 1.63B 1.60B 1.55B 1.48B 1.67B 1.78B 1.78B 1.77B 1.77B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.59B 1.61B 1.59B 1.59B 1.48B 1.48B 1.77B 1.77B 1.77B 1.77B 1.77B
Normalized Net Operating Profit after Tax (NOPAT)		 2,554 5,835 7,052 6,558 4,468 12,145 7,954 15,937 15,923 9,946 6,396
Normalized NOPAT Margin		 12.80% 25.52% 27.51% 23.24% 13.64% 36.51% 17.37% 28.36% 27.43% 18.31% 11.35%
Pre Tax Income Margin		 11.87% 29.07% 30.75% 27.39% 15.87% 25.33% 7.42% 23.11% 23.21% 11.51% 6.60%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 150.00% 64.04% 62.44% 77.36% 98.12% 80.77% 166.94% 80.19% 84.79% 216.27% 257.23%
Augmented Payout Ratio		 195.43% 215.05% 164.94% 103.92% 310.08% 94.13% 188.53% 88.28% 97.34% 257.52% 299.39%

Quarterly Metrics And Ratios for AbbVie

This table displays calculated financial ratios and metrics derived from AbbVie's official financial filings.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 1.58% -9.70% -4.92% -5.97% -5.42% 0.70% 4.31% 3.83% 5.60% 8.39% 6.65%
EBITDA Growth		 -17.93% -59.37% 41.33% -35.43% -34.51% 40.12% -10.16% 3.66% -87.92% 1.05% -10.47%
EBIT Growth		 -28.93% -83.01% 78.66% -51.99% -53.79% 137.67% -13.45% 13.78% -204.34% 3.62% -15.84%
NOPAT Growth		 -4.54% -67.34% 35.60% -49.69% -52.65% 55.75% -27.02% 38.22% -148.02% 32.44% 15.86%
Net Income Growth		 -38.89% -94.64% 118.43% -54.93% -66.67% 469.29% -32.26% -12.18% -102.79% -6.05% -31.46%
EPS Growth		 -38.05% -94.82% 123.53% -54.75% -67.86% 492.31% -32.46% -12.00% -106.67% -6.49% -32.47%
Operating Cash Flow Growth		 46.36% -14.57% 26.25% -0.37% -36.01% -3.65% -64.06% -28.08% 48.29% -59.53% 126.90%
Free Cash Flow Firm Growth		 17.75% 29.66% 45.54% 31.45% 7.00% -53.62% -78.89% -145.51% -154.55% -90.15% 0.96%
Invested Capital Growth		 -13.32% -16.52% -16.22% -19.33% -20.29% -6.93% -1.28% 17.35% 14.14% 3.48% -0.72%
Revenue Q/Q Growth		 2.09% -19.15% 13.42% 0.45% 2.69% -13.92% 17.48% -0.01% 4.44% -11.65% 15.59%
EBITDA Q/Q Growth		 -21.18% -45.41% 74.21% -13.86% -20.06% 16.80% 11.70% -0.61% -90.68% 876.75% -1.04%
EBIT Q/Q Growth		 -29.73% -73.00% 229.82% -23.27% -32.37% 38.87% 20.11% 0.87% -162.02% 237.91% -2.45%
NOPAT Q/Q Growth		 10.95% -69.38% 149.57% -40.65% 4.43% 0.70% 16.94% 12.40% -136.28% 377.75% 2.30%
Net Income Q/Q Growth		 -37.45% -90.25% 741.08% -12.14% -53.73% 66.50% 0.07% 13.91% -101.47% 5,704.35% -27.00%
EPS Q/Q Growth		 -36.65% -90.71% 776.92% -12.28% -55.00% 71.11% 0.00% 14.29% -103.41% 2,500.00% -27.78%
Operating Cash Flow Q/Q Growth		 -2.29% -43.55% 50.70% 19.86% -37.25% -15.00% -43.79% 139.85% 29.39% -76.80% 215.17%
Free Cash Flow Firm Q/Q Growth		 25.18% -3.67% 7.48% 1.42% 1.90% -58.25% -51.07% -318.61% -22.15% 107.54% 401.28%
Invested Capital Q/Q Growth		 -3.31% -3.76% -5.20% -8.56% -4.46% 12.38% 0.55% 8.70% -7.07% 1.88% -3.52%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 70.82% 66.17% 69.42% 52.96% 56.18% 65.41% 64.47% 70.87% 78.18% 68.15% 71.82%
EBITDA Margin		 37.02% 25.00% 38.40% 32.93% 25.63% 34.78% 33.07% 32.88% 2.93% 32.43% 27.76%
Operating Margin		 36.39% 22.64% 32.55% 16.38% 22.34% 22.73% 27.64% 26.49% -9.87% 27.98% 31.73%
EBIT Margin		 22.76% 7.60% 22.10% 16.88% 11.12% 17.94% 18.34% 18.50% -10.99% 17.15% 14.47%
Profit (Net Income) Margin		 16.35% 1.97% 14.62% 12.79% 5.76% 11.15% 9.49% 10.82% -0.15% 9.66% 6.10%
Tax Burden Percent		 83.37% 50.74% 77.66% 91.19% 67.99% 78.18% 63.98% 75.05% 1.01% 77.60% 60.55%
Interest Burden Percent		 86.17% 51.13% 85.18% 83.07% 76.23% 79.48% 80.92% 77.91% 136.77% 72.60% 69.62%
Effective Tax Rate		 16.63% 49.26% 22.34% 8.81% 32.01% 21.82% 36.02% 24.95% 0.00% 22.40% 39.45%
Return on Invested Capital (ROIC)		 23.01% 8.67% 19.91% 12.40% 12.92% 14.64% 15.10% 17.13% -6.41% 19.23% 17.57%
ROIC Less NNEP Spread (ROIC-NNEP)		 19.49% 6.74% 17.33% 11.83% 10.22% 13.16% 12.92% 14.76% -4.52% 16.55% 14.22%
Return on Net Nonoperating Assets (RNNOA)		 71.71% 27.49% 72.05% 43.97% 36.95% 68.28% 71.55% 89.80% -35.31% 208.92% 257.31%
Return on Equity (ROE)		 94.71% 36.16% 91.96% 56.37% 49.86% 82.92% 86.65% 106.93% -41.72% 228.15% 274.88%
Cash Return on Invested Capital (CROIC)		 35.07% 36.10% 37.98% 39.88% 38.16% 22.62% 15.71% -0.67% 4.16% 14.62% 22.12%
Operating Return on Assets (OROA)		 9.26% 3.10% 8.89% 6.71% 4.42% 6.89% 7.27% 7.35% -4.59% 6.90% 6.05%
Return on Assets (ROA)		 6.65% 0.81% 5.88% 5.08% 2.29% 4.28% 3.77% 4.30% -0.06% 3.89% 2.55%
Return on Common Equity (ROCE)		 94.54% 36.09% 91.74% 56.24% 49.74% 82.65% 86.32% 106.49% -41.49% 226.18% 271.26%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 57.20% 67.56% 53.92% 0.00% 74.98% 78.93% 85.10% 0.00% 295.99% 0.00%
Net Operating Profit after Tax (NOPAT)		 4,587 1,404 3,505 2,080 2,172 2,187 2,558 2,875 -1,043 2,897 2,963
NOPAT Margin		 30.34% 11.49% 25.28% 14.94% 15.19% 17.77% 17.69% 19.88% -6.91% 21.71% 19.21%
Net Nonoperating Expense Percent (NNEP)		 3.51% 1.93% 2.58% 0.57% 2.69% 1.47% 2.17% 2.37% -1.90% 2.68% 3.35%
Return On Investment Capital (ROIC_SIMPLE)		 5.69% - - - 3.11% - - - -1.48% 4.06% 4.21%
Cost of Revenue to Revenue		 29.18% 33.83% 30.58% 47.04% 43.82% 34.59% 35.53% 29.13% 21.82% 31.85% 28.18%
SG&A Expenses to Revenue		 22.60% 24.86% 25.59% 24.21% 20.37% 26.93% 23.35% 29.65% 43.24% 24.68% 26.43%
R&D to Revenue		 11.84% 18.75% 12.50% 12.37% 13.47% 15.75% 13.47% 14.73% 44.86% 15.49% 13.82%
Operating Expenses to Revenue		 34.43% 43.53% 36.87% 36.58% 33.84% 42.68% 36.82% 44.38% 88.05% 40.17% 40.09%
Earnings before Interest and Taxes (EBIT)		 3,441 929 3,064 2,351 1,590 2,208 2,652 2,675 -1,659 2,288 2,232
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 5,598 3,056 5,324 4,586 3,666 4,282 4,783 4,754 443 4,327 4,282
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 15.22 20.04 17.59 20.78 25.24 39.42 44.28 57.37 93.56 258.09 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 4.52 4.69 4.04 4.56 4.81 5.80 5.46 6.23 5.52 6.39 5.57
Price to Earnings (P/E)		 22.18 35.08 26.06 38.58 53.77 52.67 56.21 67.56 72.72 87.36 86.39
Dividend Yield		 3.80% 3.80% 4.51% 4.11% 4.00% 3.35% 3.57% 3.13% 3.52% 3.03% 3.47%
Earnings Yield		 4.51% 2.85% 3.84% 2.59% 1.86% 1.90% 1.78% 1.48% 1.38% 1.14% 1.16%
Enterprise Value to Invested Capital (EV/IC)		 4.45 4.70 4.29 5.03 5.43 5.83 5.58 5.89 5.76 6.54 6.12
Enterprise Value to Revenue (EV/Rev)		 5.45 5.66 4.97 5.41 5.67 6.82 6.50 7.38 6.61 7.51 6.67
Enterprise Value to EBITDA (EV/EBITDA)		 13.19 16.45 13.20 16.08 18.51 20.79 20.64 23.43 26.11 30.12 28.16
Enterprise Value to EBIT (EV/EBIT)		 20.38 29.25 22.57 30.51 38.79 40.30 40.61 44.89 63.38 72.36 70.24
Enterprise Value to NOPAT (EV/NOPAT)		 19.87 23.61 19.25 24.32 30.95 36.42 38.46 41.55 35.34 36.87 28.48
Enterprise Value to Operating Cash Flow (EV/OCF)		 12.68 13.26 10.90 11.70 13.48 16.37 19.17 24.81 19.80 26.28 20.16
Enterprise Value to Free Cash Flow (EV/FCFF)		 11.78 11.83 10.30 11.27 12.63 24.85 35.30 0.00 147.41 45.49 27.56
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 3.66 4.67 4.73 5.01 5.71 9.20 10.36 11.71 19.96 47.80 -510.73
Long-Term Debt to Equity		 3.42 4.46 4.33 4.59 5.02 7.93 8.51 9.64 17.94 44.14 -456.22
Financial Leverage		 3.68 4.08 4.16 3.72 3.61 5.19 5.54 6.08 7.82 12.63 18.09
Leverage Ratio		 8.72 9.38 10.10 9.86 9.88 13.27 14.06 15.37 19.61 29.98 41.77
Compound Leverage Factor		 7.51 4.80 8.60 8.19 7.53 10.55 11.38 11.97 26.82 21.76 29.08
Debt to Total Capital		 78.54% 82.36% 82.55% 83.36% 85.10% 90.19% 91.19% 92.13% 95.23% 97.95% 100.20%
Short-Term Debt to Total Capital		 5.13% 3.72% 7.04% 7.02% 10.30% 12.43% 16.25% 16.29% 9.65% 7.52% 10.69%
Long-Term Debt to Total Capital		 73.41% 78.64% 75.51% 76.34% 74.80% 77.77% 74.94% 75.84% 85.58% 90.44% 89.50%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.04% 0.04% 0.04% 0.05% 0.05% 0.05% 0.06% 0.05% 0.06% 0.06% 0.06%
Common Equity to Total Capital		 21.42% 17.61% 17.41% 16.60% 14.85% 9.76% 8.75% 7.82% 4.72% 1.99% -0.26%
Debt to EBITDA		 2.64 3.18 2.89 3.27 3.57 4.14 4.08 4.07 4.71 4.89 5.11
Net Debt to EBITDA		 2.24 2.82 2.46 2.54 2.78 3.12 3.30 3.63 4.30 4.50 4.61
Long-Term Debt to EBITDA		 2.47 3.04 2.65 3.00 3.14 3.57 3.35 3.35 4.23 4.51 4.56
Debt to NOPAT		 3.97 4.56 4.22 4.95 5.97 7.26 7.60 7.21 6.37 5.98 5.16
Net Debt to NOPAT		 3.38 4.05 3.59 3.84 4.65 5.46 6.16 6.44 5.82 5.51 4.67
Long-Term Debt to NOPAT		 3.71 4.36 3.86 4.53 5.25 6.26 6.25 5.94 5.73 5.52 4.61
Altman Z-Score		 1.84 1.78 1.59 1.67 1.65 1.72 1.68 1.78 1.59 1.93 1.69
Noncontrolling Interest Sharing Ratio		 0.19% 0.20% 0.24% 0.24% 0.25% 0.32% 0.38% 0.41% 0.55% 0.86% 1.32%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.96 0.96 0.89 0.96 0.87 0.94 0.81 0.65 0.66 0.76 0.74
Quick Ratio		 0.69 0.66 0.63 0.71 0.63 0.72 0.59 0.44 0.43 0.48 0.48
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 15,512 14,943 16,061 16,289 16,598 6,930 3,391 -7,413 -9,055 683 3,423
Operating Cash Flow to CapEx		 3,487.32% 2,396.00% 3,550.00% 3,458.45% 2,318.54% 2,093.26% 942.32% 2,187.55% 2,421.99% 695.74% 1,915.61%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.41 0.41 0.40 0.40 0.40 0.38 0.40 0.40 0.42 0.40 0.42
Accounts Receivable Turnover		 5.47 5.11 4.93 4.98 4.85 4.65 4.74 4.85 5.10 4.70 4.79
Inventory Turnover		 5.40 4.93 4.79 5.41 5.52 5.28 5.37 4.71 4.08 3.85 3.71
Fixed Asset Turnover		 11.56 11.34 11.32 11.22 10.95 10.98 11.04 11.02 11.13 11.23 11.32
Accounts Payable Turnover		 0.75 0.76 0.72 0.73 0.76 0.76 0.79 0.66 0.54 0.54 0.55
Days Sales Outstanding (DSO)		 66.74 71.42 74.04 73.33 75.29 78.57 77.03 75.20 71.51 77.71 76.22
Days Inventory Outstanding (DIO)		 67.58 73.97 76.18 67.50 66.12 69.16 67.97 77.42 89.39 94.74 98.30
Days Payable Outstanding (DPO)		 484.70 478.83 506.87 501.67 482.68 480.46 463.07 552.32 675.79 673.65 659.46
Cash Conversion Cycle (CCC)		 -350.37 -333.43 -356.66 -360.84 -341.27 -332.72 -318.07 -399.70 -514.89 -501.20 -484.94
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 71,088 68,417 64,859 59,310 56,662 63,674 64,026 69,598 64,674 65,888 63,566
Invested Capital Turnover		 0.76 0.75 0.79 0.83 0.85 0.82 0.85 0.86 0.93 0.89 0.91
Increase / (Decrease) in Invested Capital		 -10,925 -13,539 -12,556 -14,209 -14,426 -4,743 -833 10,288 8,012 2,214 -460
Enterprise Value (EV)		 316,377 321,218 278,344 298,520 307,792 371,297 357,373 409,620 372,436 430,958 388,821
Market Capitalization		 262,543 266,075 226,351 251,304 261,490 315,630 300,125 346,054 311,087 366,490 325,072
Book Value per Share		 $9.76 $7.50 $7.29 $6.85 $5.87 $4.53 $3.84 $3.42 $1.88 $0.80 ($0.10)
Tangible Book Value per Share		 ($46.56) ($47.36) ($46.60) ($44.53) ($43.92) ($49.54) ($49.18) ($54.30) ($51.89) ($52.31) ($52.57)
Total Capital		 80,558 75,396 73,913 72,875 69,782 82,048 77,455 77,150 70,508 71,351 70,343
Total Debt		 63,271 62,093 61,015 60,746 59,385 74,001 70,634 71,079 67,144 69,889 70,481
Total Long-Term Debt		 59,135 59,292 55,812 55,631 52,194 63,805 58,048 58,509 60,340 64,527 62,959
Net Debt		 53,801 55,114 51,961 47,181 46,265 55,627 57,205 63,527 61,310 64,426 63,704
Capital Expenditures (CapEx)		 213 175 178 219 205 193 241 249 291 235 269
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6,168 -5,023 -6,950 -9,724 -10,464 -10,524 -8,670 -9,992 -11,918 -8,542 -9,451
Debt-free Net Working Capital (DFNWC)		 3,061 1,699 1,816 3,566 2,352 7,545 4,487 -2,707 -6,363 -3,366 -2,984
Net Working Capital (NWC)		 -1,075 -1,102 -3,387 -1,549 -4,839 -2,651 -8,099 -15,277 -13,167 -8,728 -10,506
Net Nonoperating Expense (NNE)		 2,115 1,163 1,478 299 1,348 815 1,185 1,311 -1,020 1,608 2,022
Net Nonoperating Obligations (NNO)		 53,801 55,114 51,961 47,181 46,265 55,627 57,205 63,527 61,310 64,426 63,704
Total Depreciation and Amortization (D&A)		 2,157 2,127 2,260 2,235 2,076 2,074 2,131 2,079 2,102 2,039 2,050
Debt-free, Cash-free Net Working Capital to Revenue		 -10.62% -8.85% -12.41% -17.64% -19.26% -19.34% -15.76% -17.99% -21.16% -14.89% -16.20%
Debt-free Net Working Capital to Revenue		 5.27% 2.99% 3.24% 6.47% 4.33% 13.87% 8.16% -4.87% -11.30% -5.87% -5.12%
Net Working Capital to Revenue		 -1.85% -1.94% -6.05% -2.81% -8.91% -4.87% -14.73% -27.51% -23.37% -15.21% -18.01%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.39 $0.13 $1.14 $1.00 $0.46 $0.77 $0.77 $0.88 ($0.02) $0.72 $0.52
Adjusted Weighted Average Basic Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Adjusted Diluted Earnings per Share		 $1.40 $0.13 $1.14 $1.00 $0.45 $0.77 $0.77 $0.88 ($0.03) $0.72 $0.52
Adjusted Weighted Average Diluted Shares Outstanding		 1.78B 1.78B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.77B 1.76B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Normalized Net Operating Profit after Tax (NOPAT)		 4,587 1,404 3,505 2,080 2,172 2,187 2,558 2,875 -1,043 2,897 2,963
Normalized NOPAT Margin		 30.34% 11.49% 25.28% 14.94% 15.19% 17.77% 17.69% 19.88% -6.91% 21.71% 19.21%
Pre Tax Income Margin		 19.61% 3.89% 18.82% 14.02% 8.47% 14.26% 14.84% 14.41% -15.02% 12.45% 10.08%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 84.79% 134.04% 118.45% 159.78% 216.27% 177.38% 201.40% 212.33% 257.23% 265.95% 300.66%
Augmented Payout Ratio		 97.34% 160.02% 141.15% 190.03% 257.52% 200.35% 227.16% 239.43% 299.39% 300.31% 339.03%

Key Financial Trends

AbbVie Inc. (NYSE: ABBV) has demonstrated solid financial performance and strategic balance sheet management over the past four years through Q2 2025. Here are key highlights and trends derived from a detailed analysis of their quarterly cashflow statements, balance sheets, and income statements:

  • Revenue Growth: AbbVie’s operating revenue shows growth from approximately $13.0 billion in Q1 2021 to $15.4 billion in Q2 2025, signaling a steady top-line expansion driven likely by product portfolio strength and market presence.
  • Consistent Net Income: The company’s net income has increased substantially from $355 million in Q1 2021 to $941 million in Q2 2025, indicating improved profitability despite some quarterly volatility.
  • Strong Operating Cash Flow: Net cash provided by operating activities rose from $4 billion in Q1 2021 to over $5.1 billion in Q2 2025, supporting a robust cash generation capability.
  • Substantial Amortization and Depreciation: Amortization expenses steadily running above $1.8 billion every quarter highlight ongoing investments in intangible assets consistent with pharmaceutical industry practices.
  • Capital Expenditures Investment: Purchase of property, plant & equipment averages around $200-$270 million quarterly, reflecting consistent reinvestment in business infrastructure.
  • Debt Management: AbbVie manages high levels of both short-term and long-term debt, with total liabilities exceeding total equity, implying leverage which is common in pharma but needs monitoring given interest expense volatility and refinancing risk.
  • Equity Fluctuations: Total common equity has fluctuated notably, including some quarters with negative equity, primarily due to accumulated treasury stock and retained earnings, highlighting aggressive share repurchase programs balanced by earnings retention.
  • Dividend Payments: Dividends per share remained consistent at about $1.64 by Q2 2025, demonstrating commitment to shareholder returns amid earnings growth.
  • High Financing Cash Outflows: Repayments of debt and dividends regularly cause financing cash outflows exceeding $2.5 billion quarterly, which may pressure liquidity if operating cash flow fluctuates.
  • Volatile Net Income in Certain Periods: Noticeable swings including a net loss in Q4 2024 (-$23 million) and varying tax expense impacts suggest exposure to operational or non-recurring items that create earnings volatility.

Summary: Over the last four years, AbbVie has grown revenues and operating cash flows while maintaining robust investment in operations and steady dividends. The company’s financial leverage and intensive capital structure management through debt issuance and repayment highlight the strategic use of financial resources. Investors should note the occasional earnings volatility and high levels of debt but also the company’s strong cash generation, making AbbVie an established player with growth potential, especially given its industry context.

08/23/25 04:25 AMAI Generated. May Contain Errors.

Frequently Asked Questions About AbbVie's Financials

When does AbbVie's financial year end?

According to the most recent income statement we have on file, AbbVie's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has AbbVie's net income changed over the last 10 years?

AbbVie's net income appears to be on an upward trend, with a most recent value of $4.29 billion in 2024, rising from $1.77 billion in 2014. The previous period was $4.87 billion in 2023. Check out AbbVie's forecast to explore projected trends and price targets.

What is AbbVie's operating income?
AbbVie's total operating income in 2024 was $9.14 billion, based on the following breakdown:
  • Total Gross Profit: $39.43 billion
  • Total Operating Expenses: $30.29 billion
How has AbbVie's revenue changed over the last 10 years?

Over the last 10 years, AbbVie's total revenue changed from $19.96 billion in 2014 to $56.33 billion in 2024, a change of 182.2%.

How much debt does AbbVie have?

AbbVie's total liabilities were at $131.80 billion at the end of 2024, a 6.0% increase from 2023, and a 411.4% increase since 2014.

How much cash does AbbVie have?

In the past 10 years, AbbVie's cash and equivalents has ranged from $5.10 billion in 2016 to $39.92 billion in 2019, and is currently $5.52 billion as of their latest financial filing in 2024.

How has AbbVie's book value per share changed over the last 10 years?

Over the last 10 years, AbbVie's book value per share changed from 1.09 in 2014 to 1.88 in 2024, a change of 72.1%.


Related Companies

This page (NYSE:ABBV) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...
Goldco Precious Metals | Sponsoredtc pixel
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...
The Oxford Club | Sponsoredtc pixel
GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...
Priority Gold | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...
Weiss Ratings | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
Out of 18,347 Cryptocurrencies... This is the ONLY One
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...
Crypto 101 Media | Sponsoredtc pixel
Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about Presi...
InvestorPlace | Sponsoredtc pixel